menu search

Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates

Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
Patient enrollment completed for Phase 3 non-erosive gastroesophageal reflux disease (NERD) daily dosing trial with topline data for primary endpoint expected in Q1 2023 Obtained commitment for up to an additional $40 million under revenue interest financing agreement; total financing potentially available increased to $300 million Commercial launches in H. pylori, and Erosive Esophagitis […] The post Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business U... Read More
Posted: Nov 8 2022, 22:00
Author Name: forextv
Views: 111486

Search within

Pages Search Results: